BioNTech SE

ISIN US09075V1026 Symbol BNTX Industry Biotechnology Sector Healthcare
BioNTech Price
227.8USD 0.75%
1y Low: 37.0
1y High: 131.0
1y Low: 37.0
1y High: 131.0
BioNTech Analyst Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
biontech.de
Market Cap
22.9 B USD
Dividend Yield
Performance 1y
284.4 %
PER

BioNTech Stock Chart

BioNTech Dividend Chart

BioNTech Dividend Calendar

Year # Div. Div. Paid Div. Yield Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

BioNTech Performance

1 Week
8.04 %
1 Month
16.20 %
6 Months
160.5 %
Year to Date
167.7 %
1 Year
284.4 %
5 Years

BioNTech Revenue, EBIT, and Income

BioNTech Margins

BioNTech Shares Outstanding

Useful Links

Search Twitter: $BNTX, #BNTX

BioNTech Company Info

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I/II clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Eli Lilly and Company; Bayer AG; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc.; and InstaDeep Ltd. The company was founded in 2008 and is headquartered in Mainz, Germany.

BioNTech Price to Earnings Ratio (PE Ratio): —

The current Price to Earnings Ratio of BioNTech is —.
The PE Ratio is calcluated by dividing the current BioNTech share price (227.8 USD) by the earnings per share (—).

BioNTech Market Cap: 22.9 B USD

The current market cap of BioNTech is 22.9 B USD.

BioNTech Stock Price: 227.8 USD

The current stock price of BioNTech is 227.8 USD.

BioNTech ISIN: US09075V1026

The ISIN (International Securities Identification Number) of BioNTech is US09075V1026.

BioNTech Ticker Symbol: BNTX

The ticker symbol of BioNTech is BNTX.

BioNTech Address

The address of the BioNTech HQ is An der Goldgrube 12, 55131 Mainz, Germany.